Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.
Laatio L, Myllynen P, Serpi R, Rysä J, Ilves M, Lappi-Blanco E, Ruskoaho H, Vähäkangas K, Puistola U.
Tumour Biol. 2011 Oct;32(5):985-95. Epub 2011 Jun 15.
Related citations
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J.
Tumour Biol. 2011 Dec;32(6):1087-95. Epub 2011 Aug 24.
Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.
Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N.
Tumour Biol. 2011 Oct;32(5):1031-47. Epub 2011 Jul 15.
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.
Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B.
Tumour Biol. 2011 Jun;32(3):589-96. Epub 2011 Feb 26.
Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R.
Tumour Biol. 2011 Aug;32(4):831-8. Epub 2011 May 28.
MKK4 acts as a potential tumor suppressor in ovarian cancer.
Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.
Tumour Biol. 2011 Aug;32(4):661-70. Epub 2011 Apr 14.
NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma.
Peng ZY, Xiao PJ, Qi Y, Zhang W, Chen XH, Xu P.
Tumour Biol. 2011 Apr;32(2):359-66. Epub 2010 Nov 12.
Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.
Henriksen R, Sørensen FB, Ørntoft TF, Birkenkamp-Demtroder K.
Tumour Biol. 2011 Aug;32(4):671-6. Epub 2011 Mar 12.
Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
Sedláková I, Vávrová J, Tošner J, Hanousek L.
Tumour Biol. 2011 Apr;32(2):311-6.
Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.
Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, Reale MG, Frati L, Midulla C.
Tumour Biol. 2010 Oct;31(5):411-5. Epub 2010 May 20.
Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16).
Berman ZT, Moore LJ, Knudson KE, Whelan RJ.
Tumour Biol. 2010 Oct;31(5):495-502. Epub 2010 Jun 22.
Combined use of biomarkers for detection of ovarian cancer in high-risk women.
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO.
Tumour Biol. 2010 Jun;31(3):209-15.
Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.
Kellouche S, Fernandes J, Leroy-Dudal J, Gallet O, Dutoit S, Poulain L, Carreiras F.
Tumour Biol. 2010 Apr;31(2):129-39. Epub 2010 Feb 24.
HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG.
Tumour Biol. 2010 Apr;31(2):113-9. Epub 2010 Jan 23.
The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3.
Wang H, Linghu H, Wang J, Che YL, Xiang TX, Tang WX, Yao ZW.
Tumour Biol. 2010 Jan;31(1):59-67. Epub 2009 Dec 23.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on